Professor Nicholas PJ Day
Podcast interview
Infectious diseases in South East Asia
MORU aims to fight the infectious tropical diseases affecting rural communities in Asia and elsewhere in the developing world. MORU's malaria research aims to directly improve the treatment of the disease globally. It's researchers focus on the treatment of severe malaria, the spread of antimalarial drug resistance, and the pathophysiology of falciparum and vivax malaria. These studies are used to formulate novel adjuvant therapies, and have been translated into recommendations for the use of artemisinin based combination therapies.
Research groups
Colleges
Nicholas Day
MA BM BCh DM FRCP FMedSci
Professor of Tropical Medicine
- Director of the Mahidol Oxford Tropical Medicine Research Unit, Thailand, and of the Wellcome Trust Thailand Asia and Africa Programme
MORU
Nick Day's interests include the epidemiology, diagnosis, pathophysiology, pathogen biology, treatment and prevention of malaria, rickettsial diseases including scrub typhus, melioidosis, leptospirosis, rickettsial infections, influenza, dengue and other communicable diseases afflicting rural populations throughout Asia and beyond. Cross-cutting interests include the drivers and epidemiology of AMR, and the syndromic management of febrile illnesses and sepsis in LMIC settings.
Recent publications
-
Comparative analysis of targeted next-generation sequencing for Plasmodium falciparum drug resistance markers.
Kunasol C. et al, (2022), Scientific reports, 12
-
Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response.
Zhu L. et al, (2022), Communications biology, 5
-
Facilitating safe discharge through predicting disease progression in moderate COVID-19: a prospective cohort study to develop and validate a clinical prediction model in resource-limited settings.
Chandna A. et al, (2022), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
-
Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project
Chandna A. et al, (2022), Wellcome Open Research, 6, 64 - 64
-
Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial
Peto TJ. et al, (2022), The Lancet Infectious Diseases